Pharmacology/Pharmaceutical Industry
Evolution of the COVID-19 vaccine development landscape
8 Sep, 2020 | 01:18h | UTCEvolution of the COVID-19 vaccine development landscape – Nature Reviews Drug Discovery
Meta-analysis: Chloroquine and Hydroxychloroquine do not improve outcomes in COVID-19
8 Sep, 2020 | 01:08h | UTCRelated Meta-analysis: Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐analysis – Arthritis & Rheumatology
[Abstract Only] Randomized trial: Once-daily, subcutaneous vosoritide therapy in children with achondroplasia
8 Sep, 2020 | 01:06h | UTC
Commentary on Twitter
NEW Research—Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial https://t.co/LbknV5D2yL pic.twitter.com/KQvRoC58pb
— The Lancet (@TheLancet) September 7, 2020
Coalition Covid-19 Brazil – Randomized trial: Azithromycin not beneficial for patients admitted to the hospital with severe Covid-19
6 Sep, 2020 | 22:06h | UTCInvited Commentary: Azithromycin for severe COVID-19
Commentaries on Twitter
This network of Brazilian researchers has done an AMAZING job of getting organized & answering important ?s. In this Lancet article they show in a randomized trial that #azithromycin does not improve #Covid19 outcomes. @RenatoDLopes1 https://t.co/zL7GSaVqm8
— C. Michael Gibson MD (@CMichaelGibson) September 5, 2020
New trial @TheLancet does not support the routine use of azithromycin in combination with #Hydroxychloroquine in patients with severe #COVIDー19:https://t.co/vaj1XX3dSo
— Madhu Pai (@paimadhu) September 6, 2020
A living WHO guideline on drugs for Covid-19
6 Sep, 2020 | 22:04h | UTCA living WHO guideline on drugs for covid-19 – The BMJ
Commentary on Twitter
NEW #RapidRec makes a strong recommendation for systemic corticosteroids in patients with severe and critical #COVID19 and a weak or conditional recommendation against systemic corticosteroids in patients with non-severe covid-19 https://t.co/p7loBk95Vm
— The BMJ (@bmj_latest) September 5, 2020
Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine
6 Sep, 2020 | 21:44h | UTC
Russian coronavirus vaccine results have been published
6 Sep, 2020 | 21:48h | UTCCommentaries: COVID-19 vaccines: early success and remaining challenges – The Lancet AND The Russian vaccine for COVID-19 – The Lancet Respiratory Medicine AND Early-phase Russian trials reveal safety and immunogenicity of two formulations of a two-part vaccine – News Medical / The Lancet AND Russian coronavirus vaccine results have been published – here’s what they reveal – The Conversation
Commentary on Twitter
NEW—Preliminary results from Russian trials find that #COVID19 vaccine candidates led to no serious adverse events and elicit antibody response https://t.co/jGUwQa8oNd
Thread (1/8) pic.twitter.com/NWBpWDvUK3
— The Lancet (@TheLancet) September 4, 2020
[Abstract Only] Randomized trial: Aspirin increases major GI bleeding risk by 60% in older individuals
6 Sep, 2020 | 21:30h | UTCSource: EvidenceAlerts
Commentary on Twitter
Aspirin increases GI bleeding risk by 60% in an aspirin RCT
137 total GI bleeds in 90000 person years @Gut_BMJ https://t.co/Hb8h6kZrpo
— Elliot Tapper (@ebtapper) August 8, 2020
COVID-19 and mRNA vaccines—first large test for a new approach
4 Sep, 2020 | 02:08h | UTCCOVID-19 and mRNA Vaccines—First Large Test for a New Approach – JAMA
Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic
4 Sep, 2020 | 02:06h | UTC
Coalition Covid-19 Brazil – Randomized trial: Dexamethasone improves outcomes in patients with Acute Respiratory Distress Syndrome and COVID-19
3 Sep, 2020 | 11:24h | UTCEditorial: Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic
Related studies: Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial – JAMA AND Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial – JAMA
Commentary: Inexpensive Steroids Can Save Lives Of Seriously Ill COVID-19 Patients – NPR
Commentary on Twitter
In this RCT, IV #dexamethasone increased the number of ventilator-free days by day 28 vs standard care alone among patients with #COVID19 and moderate or severe ARDS https://t.co/RA9G6LVRlz @ICURevisited @FlaviaSepsis @israelmaia16
— JAMA (@JAMA_current) September 2, 2020
Video: Corticosteroids for COVID-19 – New Evidence of Benefit
3 Sep, 2020 | 11:21h | UTCCorticosteroids for COVID-19 – New Evidence of Benefit – JAMA
Meta-analysis: Corticosteroids for critically ill patients with COVID-19
3 Sep, 2020 | 11:23h | UTCEditorial: Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic
Commentaries: Analysis of seven trials finds that corticosteroids reduce risk of death by 20 per cent in critically ill COVID-19 patients – University of Bristol AND Multiple studies confirm steroids can fight severe COVID-19 – MedicalXpress
Commentary on Twitter
1/8 Corticosteroids and COVID19
*Three* RCTs and a new @WHO meta-analysis add to #RECOVERY trial data that corticosteroids reduce mortality in critically ill #COVID19 patientshttps://t.co/H8c46Y5DTm— JAMA (@JAMA_current) September 2, 2020
Incidence of malformations after early pregnancy exposure to Modafinil
4 Sep, 2020 | 02:02h | UTCIncidence of Malformations After Early Pregnancy Exposure to Modafinil in Sweden and Norway – JAMA (free for a limited period)
Commentary: Narcolepsy drug did not increase risk of fetal malformation – Karolinska Institutet
Commentary on Twitter
Cohort study: Modafinil use during early pregnancy was not significantly associated with increased risk of major malformations (unexposed group = 2.1% vs. exposed = 2.6%; crude RR = 1.06; 0.35-3.26). 1st trimester only: RR = 0.44; 0.06-3.10 https://t.co/u4WsK2v31C
— PfOL (@psychopharmacol) September 2, 2020
New WHO Guidance: Corticosteroids for COVID-19
3 Sep, 2020 | 11:20h | UTCCorticosteroids for COVID-19 – World Health Organization
News Release: WHO updates clinical care guidance with corticosteroid recommendations – World Health Organization
Commentaries: The WHO Now Recommends Cheap Steroids As a Life-Saving Treatment for Severe Covid-19 – Gizmodo AND Inexpensive steroids reduce deaths of hospitalized Covid-19 patients, WHO analysis confirms – STAT
Commentary on Twitter
? guideline on use of dexamethasone & other corticosteroids advises:
✅ for oral or intravenous usage in treatment of patients with severe & critical #COVID19
❌ against usage in treatment of non-severe casesMore: https://t.co/eWHzRrYKvO
— World Health Organization (WHO) (@WHO) September 2, 2020
[Preprint] Randomized trial: Tocilizumab does not improve clinical status or mortality in hospitalized patients with COVID-19 pneumonia
3 Sep, 2020 | 11:19h | UTCTocilizumab in Hospitalized Patients With COVID-19 Pneumonia – medRxiv
Fauci says COVID vaccine trials could end early if results are overwhelming
3 Sep, 2020 | 11:02h | UTCFauci Says COVID Vaccine Trials Could End Early If Results Are Overwhelming – Kaiser Health News
[Abstract Only] CAR T-cell therapy for patients with relapsed or refractory large B-cell lymphomas
3 Sep, 2020 | 10:56h | UTCLisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study – The Lancet (link to abstract – $ for full-text)
U.S. advisory group lays out detailed recommendations on how to prioritize Covid-19 vaccine
2 Sep, 2020 | 09:46h | UTCU.S. advisory group lays out detailed recommendations on how to prioritize Covid-19 vaccine – STAT
ADA Guideline synopsis: Pharmacologic approaches to glycemic treatment of Type 2 Diabetes
2 Sep, 2020 | 09:41h | UTC
#ESCCongress – [Not Published Yet] First randomized trial backs safety of ACE Inhibitors and ARBs in COVID-19 patients
2 Sep, 2020 | 09:48h | UTCNews Release: First randomised trial backs safety of common heart drugs in COVID-19 patients – European Society of Cardiology
Commentary on Twitter
Dr. Renato Lopes presents the BRACE CORONA trial: in patients hospitalized with COVID-19, suspending ACEI/ARB therapy for 30 days did not impact the number of days alive and out of hospital.
Full slide deck: https://t.co/avSK41bGSj#ESCCongress pic.twitter.com/2p0FH9U2RG
— C. Michael Gibson MD (@CMichaelGibson) September 1, 2020
Anticoagulation in COVID-19: A systematic review, meta-analysis and rapid guidance from the Mayo Clinic
1 Sep, 2020 | 06:26h | UTC
Viewpoint – Regulatory decision-making on COVID-19 vaccines during a public health emergency
1 Sep, 2020 | 06:08h | UTCRegulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency – JAMA
Viewpoint – Emergency use authorizations during the COVID-19 pandemic: Lessons from hydroxychloroquine for vaccine authorization and approval
1 Sep, 2020 | 06:09h | UTC
#ESCCongress – [Abstract Only] Randomized trial: Colchicine in patients with chronic coronary disease
1 Sep, 2020 | 06:04h | UTCColchicine in Patients with Chronic Coronary Disease – New England Journal of Medicine
Commentaries: LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease – TCTMD AND Low Dose Colchicine for Secondary Prevention of Cardiovascular Disease 2 – LoDoCo2 – American College of Cardiology
Commentary on Twitter
Patients with chronic coronary disease were randomized to daily colchicine or placebo. Incidence of the composite endpoint of cardiovascular death, spontaneous MI, ischemic stroke, or ischemia-driven coronary revascularization was significantly lower with colchicine. #ESCCongress
— NEJM (@NEJM) August 31, 2020